Characteristics and prognosis of DDX41- and GATA2-mutated myeloid neoplasms. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback